A 12-Month Real-Life Study of Eptinezumab for Preventing High-Frequency Episodic and Chronic Migraine

What this Trial Is About

Researchers are evaluating the effectiveness, safety, and tolerability of eptinezumab in people with high frequency episodic and chronic migraine. This real-world, multicenter study involves patients who experience frequent disabling migraines or chronic headaches, aiming to observe how eptinezumab works outside of controlled clinical trials. The study administers eptinezumab intravenously every three months at doses of either 100 mg or 300 mg, depending on the patients needs. This treatment is given in Italian headache centers over a 12-month period. Patients receive the medication quarterly, and the dose may be increased after the first infusion if necessary. Participants will be monitored for changes in the number of migraine or headache days over 12, 24, and 48 weeks compared to their baseline. Researchers will also track safety by recording any side effects during the year-long treatment. Additional assessments include changes in pain medication use, headache impact, migraine disability, pain intensity, and patient global impression of change. This comprehensive monitoring helps understand the treatments real-life effects and tolerability.

EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.